47 results about "Myeloproliferative Disorders" patented technology

The present invention provides methods of modulating mammalian, particularly human, stem cell and progenitor cell differentiation to regulate and control the differentiation and maturation of these cells along specific cell and tissue lineages. The methods of the invention relate to the use of certain small organic molecules to modulate the differentiation of stem cell populations along specific cell and tissue lineages, particularly embryonic-like stem cells originating from a postpartum placenta or stem cells isolated form sources such as cord blood. The invention also relates to the treatment or prevention of myelodysplastic syndrome or myeloproliferative syndrome, or symptoms thereof, comprising administration of JNK or MKK inhibitors, alone or in combination, as well as with or without the use of unconditioned cells or cells conditioned in accordance with other aspects of the invention. Finally, the invention relates to the use of such differentiated stem cells in transplantation and other medical treatments.

The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of cancer and myeloproliferative disorders. The invention also provides methods of identifying anti-cancer agents.

The present invention relates to pyrazolopyridines and imidazopyridines which are inhibitors of the kinase PDK1 and are thus useful for the treatment of myeloproliferative disorders or cancer. The compounds are also useful as inhibitors of other kinases such as FGFR3, NTRK3, RP-S6K and WEE1. Furthermore, the present compounds also selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease.

The present invention provides inhibitors of kinases, specifically IκB kinases, JAK1, JAK2, JAK3 and TYK2. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting said kinase activity by administering the compound to a patient in need of treatment for myeloproliferative disorders, cancer or NF-κB-mediated diseases.

The present invention relates to compounds of Formula (I) and to their pharmaceutical compositions, and to their methods of use. These novel compounds provide a treatment for myeloproliferative disorders and cancer.

In part, the present disclosure relates methods for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or one or more complications of a myeloproliferative disorder. The present disclosure further relates methods for treating, preventing, or reducing the severity of a Janus kinase-associated disorder or one or more complications of a Janus kinase-associated disorder. In certain aspects the disclosure provides TβRII antagonists for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or a Janus kinase-associated disorder or one or more complications of a myeloproliferative disorder or a Janus kinase-associated disorder.

The invention discloses a new use of T-2 toxin, that is, application of T-2 toxin in the preparation of drugs for treating bone cancers and myeloproliferative disorder, wherein the curative dose thereof is 0.1-20 mg/Kg (weight), preferably 0.5-8 mg/Kg (weight), during drug administration, the method comprises oral administration, intravenous injection, hypodermic injection and intramuscular injection. The invention establishes animal or cell models of multiple myeloma, osteosarcoma and myelodysplastic syndrome, and inspects the inhibition of the T-2 toxin on the tumors or tumor cells by injection or cell co-culture. The experiment shows that the T-2 toxin is capable of inhibiting the growth of tumor cells and has good killing effect on the bone cancers and myeloproliferative disorder.

The present application relates to securinine or norsecurinine analogues that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases. The agents may also be used as a myeloablative agent in conjunction with a bone marrow transplant or stem cell therapy.

The invention discloses application of a medicine composition in preparing medicine for treating osteocarcinoma and myeloproliferative disorder. The medicine composition includes GATA polypeptide, and can also be jointly administrated with bortezomib. The effective therapeutic dose of the medicine composition is 0.1-20 mg/Kg (body weight), and the medicine composition can be administrated in an oral mode or a mainline mode or a subcutaneous injection mode or an intramuscular injection mode in the administrating process. It is shown through experiments that polypeptide can inhibit growth of tumor cells, a good inhibiting effect on osteocarcinoma and myeloproliferative disorder is achieved, and wide application can be achieved.

Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have myeloproliferative disorders, such as Essential Thrombocythemia (ET). Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having myeloproliferative disorders, such as ET.

Screening assays and methods of using same for screening to identify modulator agents or compounds that target endoplasmic reticulum stress related signaling pathways to induce apoptosis are described herein. Pharmaceutical compositions comprising modulator agents or compounds identified by screening assays described herein are also encompassed. Methods for treating a myeloproliferative disorder characterized by monoclonal plasma cell proliferation in a subject using the aforementioned modulator agents or compounds are also envisioned. Modulator agents or compounds thereof for use in treating a myeloproliferative disorder in a subject and use of modulator agents or compounds thereof in the preparation of medicaments for the treatment of a myeloproliferative disorder are also encompassed herein. Exemplary myeloproliferative disorders include: monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and multiple myeloma (MM).

The invention relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine decoction for treating a myeloproliferative disorder syndrome. The traditional Chinese medicine decoction is prepared from the following traditional Chinese medicine raw materials by weight percentage: 6-9% of Japanese polygala, 7-10% of cornu bubali, 6-9% of fructus polygoni orientalis, 8-10% of herba rabdosiae, 6-8% of plantain herb, 2-5% of vervain, 5-8% of lalang grass rhizome, 3-5% of prismatomeris tetrandra, 2-4% of lignum dalbergiae odoriferae, 2-5% of herba orostachyos, 3-6% of rhizoma smilacis glabrae, 2-4% of kelp, 2-4% of changium smyrnioides, 2-5% of bunge corydalis herb, 2-4% of fructus gardeniae praeparatus, 1-3% of oviductus ranae, 1-3% of folium artemisiae argyi, 1-3% of agilawood, 2-4% of fructus aurantii immaturus, 4-7% of poria, 2-5% of purslane and 2-4% of pyrrosia lingua. The decoction has a high curative effect on treating the myeloproliferative disorder syndrome, is free of toxic or side effect, and has the effects of clearing away heat and toxic materials, cooling blood, enriching the blood, promoting the circulation of qi, restoring a menstrual flow, stop bleeding by astringency, supporting yang, dissolving phlegm, resolving a hard lump, promoting blood circulation, diminishing swelling, alleviating pain, nourishing yin, tonifying a kidney, filling marrow, strengthening a spleen, nourishing the blood, preventing a cancer and the like, completely suppresses a malignant abnormal clone hyperplasia myeloid tissue, thoroughly restores immunodeficiency of an organism, improves resistance and has a total effective rate of 85.9%.